Sign In
Buy REPL
$9.52
-0.160 (-1.65%)
At Close: Jul 16, 2026
Replimune: Interesting Developer Of Oncolytic Immunotherapies
03:03am, Sunday, 06'th Dec 2020
Replimune is developing a handful of oncolytic immunotherapies therapies targeting cancers. The company has nearly half a billion dollars in cash.
2 Biotech Stocks That Could Have Tripled Your Money This Year
08:39am, Sunday, 15'th Nov 2020
One has a better chance to keep climbing than the other does.
Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update
08:00am, Thursday, 05'th Nov 2020
RP1 : Updated deep and durable response data with Opdivo ® in CSCC and anti- PD1 failed melanoma continue to support ongoing registration-directed development
2 Top Biotech Stocks From the IPO Class of 2018 to Buy Now
07:24am, Wednesday, 04'th Nov 2020
Compelling clinical trial results so far make these biotech stocks worth more attention than they've received so far.
